Skip to content

Because every cancer patient deserves the best shot at a cure

BetaGlue® Therapeutics introduces YntraDose® – an innovative radiotherapy platform for the targeted and personalised treatment of solid tumours.

By offering a novel easy-to-use interventional oncology treatment option YntraDose® is set to become the new standard of care for a wide range of solid tumour cancer patient groups where current approaches fall short.

Technology

The YntraDose radiotherapy platform is set to enable an entirely new treatment option for the benefit of patients and healthcare professionals alike.

Clinical Data

YntraDose has demonstrated preliminary safety and effectiveness in clinical use. Hear what the clinicians have to say about the potential of our technology.

Pipeline

YntraDose is inherently versatile and has the potential to treat a wide range of solid tumour cancer patient groups.

Leadership Team

Meet BetaGlue’s leadership team, main board and clinical advisory board.

Our mission

By offering a novel easy-to-use interventional oncology treatment option YntraDose is set to become the new standard of care for a wide range of solid tumour cancer patient groups where current approaches fall short.

Contact us

To find out more about our pipeline, or to work for us, or to understand YntraDose further, get in touch with us